Protagen AG, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH (all based in Germany) have joined forces in an attempt to improve in silico methods to predict how patients will respond to immunotherapy in malignant melanoma. The group want to develop and apply deep machine-learning to explore biomarkers for relevant endpoints – including clinical response and survival.
To find out more about how the collaboration came about and why a predictive approach to immunotherapy is so important, we spoke with the diagnostics biotechnology company, Protagen.